Parametric Portfolio Associates LLC lifted its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 4.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 137,200 shares of the biotechnology company’s stock after buying an additional 6,293 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.13% of Innoviva worth $1,756,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Victory Capital Management Inc. grew its position in shares of Innoviva by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 9,967 shares of the biotechnology company’s stock worth $128,000 after buying an additional 1,494 shares during the period. Profund Advisors LLC grew its position in shares of Innoviva by 8.8% during the 2nd quarter. Profund Advisors LLC now owns 15,220 shares of the biotechnology company’s stock worth $195,000 after buying an additional 1,227 shares during the period. State of Alaska Department of Revenue grew its position in shares of Innoviva by 79.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 15,327 shares of the biotechnology company’s stock worth $196,000 after buying an additional 6,767 shares during the period. TrimTabs Asset Management LLC acquired a new stake in shares of Innoviva during the 2nd quarter worth approximately $206,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Innoviva during the 2nd quarter worth approximately $214,000. Institutional investors own 69.99% of the company’s stock.

INVA has been the topic of several recent analyst reports. Cowen and Company set a $16.00 price objective on shares of Innoviva and gave the stock a “buy” rating in a research note on Monday, October 23rd. ValuEngine raised shares of Innoviva from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Zacks Investment Research raised shares of Innoviva from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Wednesday, October 25th. Robert W. Baird reissued a “hold” rating and set a $13.00 price objective on shares of Innoviva in a research note on Tuesday, October 24th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $15.00 price objective on shares of Innoviva in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Innoviva currently has an average rating of “Hold” and a consensus target price of $13.60.

Innoviva, Inc. (NASDAQ INVA) opened at $12.59 on Friday. Innoviva, Inc. has a one year low of $10.07 and a one year high of $14.87. The firm has a market cap of $1,376.84, a P/E ratio of 14.47 and a beta of 2.51. The company has a debt-to-equity ratio of -2.59, a quick ratio of 7.31 and a current ratio of 6.71.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.34 by ($0.13). Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The firm had revenue of $48.64 million for the quarter, compared to the consensus estimate of $57.18 million. During the same period in the previous year, the business earned $0.13 EPS. The firm’s revenue was up 46.0% compared to the same quarter last year. analysts forecast that Innoviva, Inc. will post 1.08 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Parametric Portfolio Associates LLC Has $1.76 Million Stake in Innoviva, Inc. (INVA)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/12/parametric-portfolio-associates-llc-has-1-76-million-stake-in-innoviva-inc-inva.html.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. (NASDAQ:INVA).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Stock Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related stocks with our FREE daily email newsletter.